City
Epaper

Death risk from Covid-triggered heart issues very high in first 30 days of infection

By IANS | Updated: October 25, 2022 17:15 IST

New Delhi, Oct 25 The risk of death from heart attack or failure after Covid-19 is very high ...

Open in App

New Delhi, Oct 25 The risk of death from heart attack or failure after Covid-19 is very high within the first 30 days of infection, but remains heightened for some time afterwards, a new research has revealed.

The large UK Biobank study published online in the journal Heart, linked Covid to a heightened risk of poor cardiovascular health and death, particularly among those whose infection is severe requiring hospital admission.

Most cardiovascular disease diagnoses, especially atrial fibrillation, VTE (blood clot in a vein), pericarditis, and death from any cause occurred within the first 30 days of infection and among those admitted to hospital for Covid-19 as the primary reason.

But heightened risk remained beyond 30 days, particularly for heart failure, atrial fibrillation, VTE, pericarditis and all-cause deaths, although to a lesser extent, the observational study showed.

Unsurprisingly, deaths were higher among people with Covid-19 infection: those admitted with the virus as a primary reason were 118 times as likely to die as those who didn't need hospital treatment, while those for whom Covid-19 was a secondary diagnosis were 64 times as likely to die.

"The long-term sequelae of past Covid-19 exposure is emerging as a dominant public health concern. Our findings highlight the increased cardiovascular risk of individuals with past infection, which are likely to be greater in countries with limited access to vaccination and thus greater population exposure to Covid-19," said the researchers.

To reach the conclusion, the researchers drew on 53,613 UK Biobank participants, 17,871 of whom were diagnosed with Covid-19 infection between March 2020 and March 2021, and 35,742 of whom weren't.

Of the 17,871 Covid-19 cases, 2,701 required hospital admission for their infection; 866 were admitted to hospital for another condition; and 14,304 didn't need hospital treatment.

All participants were tracked until a cardiovascular problem arose, they died, or until the end of March 2021, providing 141 days of monitoring, on average, but ranging from 32 to 395.

Compared with their matched peers who hadn't caught the virus, those who didn't require hospital admission for Covid-19 infection were nearly 3 times as likely to have a blood clot in a vein (VTE) and more than 10 times as likely to die of any cause.

In a linked editorial, doctors from the Centre for Cardiovascular Science, University of Edinburgh, UK, said that the prothrombotic effects of Covid-19 do raise the question of whether antithrombotic strategies are required to prevent this large excess of events".

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: ukNew DelhiUniversity Of EdinburghThe new delhi municipal councilDelhi south-westBiobankNew-delhi
Open in App

Related Stories

CricketIND-W vs AUS-W, 3rd ODI: Australia Women Win Toss, Opt to Bat Against India in Series Decider; Check Playing XIs

CricketWhy Is India Women’s Cricket Team Wearing a Pink Jersey in IND-W vs AUS-W 3rd ODI 2025 Match?

CricketIND-W vs AUS-W 3rd ODI LIVE Cricket Streaming: When and Where to Watch India Women vs Australia Women Final Match

LifestyleGanpati Visarjan in London: Videos Show Indians Taking Out Ganesh Idol Immersion Procession With Band

NationalDelhi: 8 Accused in Vehicle Theft Cases Arrested During Police Patrolling, Stolen Scooters and Bikes Recovered

Health Realted Stories

HealthRajasthan govt bans cough syrup after patients fall ill in Bharatpur and Sikar

HealthScience innovation accelerates development: MP Minister

HealthCardiology Beyond Stents - How Terna Hospital Manages Heart Failure Holistically

HealthNew blood test to predict risk of liver cirrhosis, cancer within 10 years

HealthIndia must ensure equitable, timely access to lenacapavir to tackle global HIV cases